Adamis Pharmaceuticals Schedules Second Quarter 2019 Earnings Conference Call and Business Update

On August 5, 2019 Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis"), a specialty biopharmaceutical company primarily focused on developing and commercializing products in the therapeutic areas of allergy, respiratory disease and opioid overdose, reported that it will host an investor conference call on Thursday, August 8, 2019 at 2:00 pm Pacific Time to discuss its financial and operating results for the second quarter of 2019 as well as provide an update on business developments and activities (Press release, Adamis Pharmaceuticals, AUG 5, 2019, View Source [SID1234538138]). The company’s press release concerning its second quarter 2019 financial results will be available after 1:00 p.m. Pacific Time on August 8, 2019, on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly report on Form 10-Q for the second quarter ended June 30, 2019, on that date.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Adamis Pharmaceuticals Second Quarter 2019 Conference Call

Date:Thursday, August 8, 2019

Time:2:00 pm PT (5:00 pm ET)

U.S. Dial-in (Toll Free): 1-866-288-0540

TOLL/International Dial-in: 1-323-994-2131

Conference ID: 4399286

Dr. Dennis J. Carlo, President and CEO of Adamis, will host the call along with other members of the management team. The call is open to the public and will provide an update on recent developments, events that have taken place during this quarter and certain target milestones and goals for future periods. Forward-looking statements concerning expectations regarding future company performance may be made during the conference call.

A live audio webcast of the conference call will also be available via this link – View Source Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 5:00 pm PT on August 8, 2019. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll). Please use the replay PIN number 4399286.

Altimmune to Announce Second Quarter 2019 Financial Results on August 14

On August 5, 2019 Altimmune, Inc. (Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, reported that it will report financial results for the three and six months ended June 30, 2019 before the market open and host a conference call on Wednesday, August 14, 2019 (Press release, Altimmune, AUG 5, 2019, View Source [SID1234538137]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Conference Call Details
Date: Wednesday, August 14
Time: 8:30 am Eastern Time
Domestic: 877-423-9813
International: 201-689-8573
Conference ID: 13692577
Webcast: View Source

VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference

On August 5, 2019 VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI"), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported that Jeff Baxter, President and CEO, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston, MA, on Thursday, August 8, 2019, at 1:30 PM ET (Press release, VBI Vaccines, AUG 5, 2019, View Source [SID1234538136]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: Canaccord Genuity 39th Annual Growth Conference
Date: Thursday, August 8, 2019
Time: 1:30 – 1:55 PM ET
Webcast: View Source

A live webcast of the presentation and a subsequent replay may be accessed by visiting the Investors page of VBI’s website at www.vbivaccines.com. A replay of the webcast will be archived on the company’s website for 90 days following the presentation.

VBL Therapeutics to Report Second Quarter 2019 Financial Results on August 13

On August 5, 2019 VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, reported that it will host a conference call and live audio webcast on Tuesday, August 13 at 8:30am Eastern Time to report second quarter and six-months ended June 30, 2019 financial results and to provide a corporate update (Press release, VBL Therapeutics, AUG 5, 2019, View Source [SID1234538135]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Tuesday, August 13th @ 8:30am Eastern Time
From the US: 877-407-9208
International: 201-493-6784
Conference ID: 13692422
Webcast: Webcast

Syndax to Participate in the BTIG Biotechnology Conference

On August 5, 2019 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology therapies at the BTIG Biotechnology Conference on Monday, August 12, 2019 at 4:00 p.m. ET at the St. Regis New York (Press release, Syndax, AUG 5, 2019, View Source [SID1234538134]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!